US Stock Insider Trading | Ptc Therapeutics disclosed four insider transactions on February 23

K-LinePoet · 2026-02-24T15:07:42+00:00

On February 23, 2026, Ptc Therapeutics disclosed insider trading activities by executives and directors. Boulding Mark Elliott sold 1,629 shares on February 19, and other executives and directors also conducted multiple sell transactions on February 18, totaling several hundred thousand dollars. The company focuses on the biopharmaceutical field, particularly on treatments for genetic diseases.

K-LinePoet

2026-02-24 15:07:42

Abstract generation in progress

On February 23, 2026, Ptc Therapeutics (PTCT) disclosed four insider transactions. Executive Boulding Mark Elliott sold 1,629 shares on February 19, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Executive	Boulding Mark Elliott	February 19, 2026	Sell	800	68.54	$54,800
February 23, 2026	Executive	Boulding Mark Elliott	February 19, 2026	Sell	2,219	69.82	$154,900
February 20, 2026	Executive	Almstead Neil Gregory	February 18, 2026	Sell	3,121	69.36	$216,500
February 20, 2026	Director	Klein Matthew B.	February 18, 2026	Sell	7,371	69.36	$511,300
February 20, 2026	Executive	Pauwels Eric	February 18, 2026	Sell	3,019	69.36	$209,400
February 20, 2026	Executive	Gravier Pierre	February 18, 2026	Sell	2,992	69.36	$207,500
February 20, 2026	Executive	Utter Christine Marie	February 18, 2026	Sell	2,494	69.36	$173,000
February 20, 2026	Executive	Golden Lee Scott	February 18, 2026	Sell	2,484	69.36	$172,300
February 19, 2026	Executive	Boulding Mark Elliott	February 17, 2026	Sell	2	70.13	$140.30
February 19, 2026	Executive	Boulding Mark Elliott	February 17, 2026	Sell	2,811	69.29	$194,800

【Company Information】

Ptc Therapeutics, Inc. was incorporated on March 31, 1998, as a Delaware corporation. PTC Therapeutics is a biopharmaceutical company focused on oral drugs for post-transcriptional control processes, discovering and developing proprietary small-molecule medicines. The company’s R&D programs target multiple therapeutic areas, with a particular focus on developing and commercializing treatments for orphan and ultra-orphan rare diseases. The lead candidate is ataluren, used to treat a genetic disorder caused by nonsense mutation genes.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.